神经母细胞瘤患者血清NSE和VEGF水平测定及其临床意义

Clinical significance of serum level of NSE and VEGF in patients with neuroblastoma

目的:探讨神经母细胞瘤(NB)患者血清神经元特异性烯醇酶(NSE)和血管内皮生长因子(VEGF)水平测定及其临床意义。方法:选用电化学发光法检测患者血清NSE和酶联免疫吸附试验(ELISA)检测患者血清VEGF水平,并取健康儿童血清作为对照。结果:初治组患者血清NSE和VEGF水平明显高于对照组[(62.1±31.2)U/ml、(510.23±212.3)ng/L]vs[(14.2±4.2)U/ml、(201.1±68.9)ng/L]。复发组NSE和VEGF水平分别为(58.9±29.9)U/ml、(501.35±216.6)ng/L明显高于对照组(P<0.01)。患者治疗有效组较治疗前NSE和VEGF水平明显降低[(40.17±12.22)U/ml、(255.17±152.13)ng/L]vs[(101.17±32.29)U/ml、(481.55±250.41)ng/L](P<0.01)。初诊时血清NSE与VEGF水平经Spearman等级相关分析呈正相关。结论:NSE和VEGF水平是神经母细胞瘤负荷指标,提示血清NSE和VEGF水平可作为监测神经母细胞瘤的疗效、复发与预后的辅助性指标。

Objective：To investigate the clinical significance of serum neuron specific enolase（NSE） and vascular endothelial growth factor（VEGF） level in patients with neuroblastoma（NB）.Methods： The serum NSE levels were detected by electro chemiluminescence,the serum VEGF levels were detected by ELISA assay in NB patients and healthy children as control.Results： The serum levels of NSE and VEGF in initially treated patients were significantly higher than those in healthy children [（62.1±31.2） U/ml,（510.23±212.3）ng/L vs（14.2 ±4.2） U/ml,（201.1±68.9）ng/L]（P0.01）.The serum levels of NSE and VEGF from the patients who received CR in post-treatment patients were significantly lower than those in pre-treated patients [（40.17±12.22） U/ml、（255.17±152.13）ng/L] vs[（101.17±32.29） U/ml,（481.55±250.41）ng/L]（P0.01）.Conclusion： The serum levels of NSE and VEGF are effective indexes in neuroblastoma patients,so they are auxiliary indexes in monitoring curative effect diagnosing recurrence and evaluating prognosis in neuroblastoma.